Global Cord Blood Corporation (NYSE: CO) reported its fourth quarter fiscal 2020 results, showcasing a 19.2% increase in revenues to RMB299.9 million ($42.4 million), driven by 18,488 new subscribers, totaling 833,094 subscribers. Operating income surged 68.1% to RMB149.3 million ($21.1 million), and non-GAAP operating income rose 58.7% to RMB161.7 million ($22.8 million). However, net cash from operations fell 59.4% to RMB90.0 million ($12.7 million), impacted by COVID-19 challenges.
Global Cord Blood Corporation (NYSE: CO), China's top provider of cord blood services, will release its financial results for Q4 and full-year fiscal 2020 on June 29, 2020, post-market close. A conference call is scheduled for June 30, 2020, at 8:00 AM ET to discuss the financial performance and recent developments. Interested parties can listen via the IR website or by phone. The company's comprehensive services include cord blood collection, laboratory testing, and stem cell storage, enhancing its market leadership in China.